Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms
Companies Search For Novel Modalities, Enabling Technology
Executive Summary
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.